Last reviewed · How we verify

ORIYOMI OMOTOYOSI AKINYOTU — Portfolio Competitive Intelligence Brief

ORIYOMI OMOTOYOSI AKINYOTU pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sulphadoxine-Pyrimethamine Sulphadoxine-Pyrimethamine marketed Antifolate antimalarial Dihydrofolate reductase; dihydropteroate synthase Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centers for Disease Control and Prevention · 1 shared drug class
  2. Radboud University Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ORIYOMI OMOTOYOSI AKINYOTU:

Cite this brief

Drug Landscape (2026). ORIYOMI OMOTOYOSI AKINYOTU — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oriyomi-omotoyosi-akinyotu. Accessed 2026-05-17.

Related